The contribution of altered neuronal autophagy to neurodegeneration.

Alzheimer's disease Autophagy Central nervous system Neurodegeneration Neurons Parkinson's disease Spinal cord injury Traumatic brain injury

Journal

Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840

Informations de publication

Date de publication:
10 2022
Historique:
received: 07 02 2022
revised: 22 03 2022
accepted: 23 03 2022
pubmed: 31 3 2022
medline: 4 10 2022
entrez: 30 3 2022
Statut: ppublish

Résumé

Defects in cellular functions related to altered protein homeostasis and associated progressive accumulation of pathological intracellular material is a critical process involved in the pathogenesis of many neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Autophagy is an essential mechanism that ensures neuronal health by removing long-lived proteins or defective organelles and by doing so prevents cell toxicity and death within the central nervous system. Abundant evidence has shown that neuronal autophagy pathways are altered in Alzheimer's disease, Parkinson's disease and traumas of the central nervous system including Spinal Cord Injury and Traumatic Brain Injury. In this review, we aimed to summarize the latest studies on the role that altered neuronal autophagy plays in brain health and these pathological conditions, and how this knowledge can be leveraged for the development of novel therapeutics against them.

Identifiants

pubmed: 35351465
pii: S0163-7258(22)00072-9
doi: 10.1016/j.pharmthera.2022.108178
pmc: PMC9510148
mid: NIHMS1795086
pii:
doi:

Types de publication

Journal Article Review Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

108178

Subventions

Organisme : NIA NIH HHS
ID : RF1 AG055707
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG056689
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All the authors have no competing interest to declare.

Auteurs

Alessia Filippone (A)

Alzheimer's Center at Temple, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D' Alcontres 31. 98166 Messina, Italy.

Emanuela Esposito (E)

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D' Alcontres 31. 98166 Messina, Italy.

Deborah Mannino (D)

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D' Alcontres 31. 98166 Messina, Italy.

Nicholas Lyssenko (N)

Alzheimer's Center at Temple, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.

Domenico Praticò (D)

Alzheimer's Center at Temple, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA. Electronic address: praticod@temple.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH